Welcome to
The TAPESTRY AUTISM Study
If your child has a diagnosis of autism and struggles with irritability, they may qualify to participate in our clinical trial of a potential new treatment.
-
Are age 13 to 17
-
Have been diagnosed with ASD
-
Experience irritability
Who is this study for?
Male or female teens may qualify for this study if they meet the following criteria:
A New Approach to Treating Autism-Related Irritability
The clinical trial is evaluating an experimental drug, AB-2004, that offers a novel approach for the treatment of irritability associated with Autism Spectrum Disorder (ASD). This study builds upon research that has shown there is a significant difference in the bacteria located in the gut, or digestive tract, of children with autism compared to those children who are not on the autism spectrum. Scientific evidence has demonstrated there may be a link between gut bacteria and the brain which could contribute to certain characteristics, such as irritability, in children with ASD.
AB-2004, which is a powder, is designed to selectively adsorb substances produced by bacteria in the gut and reduce their ability to enter the bloodstream and contribute to certain characteristics like irritability. The TAPESTRY Study is a placebo-controlled clinical trial that aims to show that treatment with AB-2004 can improve irritability in children with ASD. Eligible participants will be randomly assigned to receive AB-2004 or placebo.
Who is this study for?
Male or female teens may qualify for this study if they meet the following criteria:
-
Are age 13 to 17
-
Have been diagnosed with ASD
-
Experience irritability
The TAPESTRY Study trial coordinator will complete screening assessments to determine if your child is suitable for this study.
What will participants receive?
If your child qualifies for this study, they will receive, at no cost:
-
The investigational drug or placebo
-
All study-related assessments conducted by trained staff at our clinical sites
Health insurance is not required to take part in this study.
Where are the study locations?
The TAPESTRY study is being conducted at 25 major clinical centers in the United States, Australia and New Zealand.